Hendrik Andreas Wolff1, Jochen Gaedcke2, Klaus Jung3, Robert Michael Hermann1,4, Hilka Rothe5, Markus Schirmer6, Torsten Liersch2, Markus Karl Alfred Herrmann1, Steffen Hennies1, Margret Rave-Fränk1, Clemens Friedrich Hess1, Hans Christiansen7,8. 1. Department of Radiotherapy and Radiooncology, University Medicine Göttingen, Göttingen, Germany. 2. Department of Surgery, University Medicine Göttingen, Göttingen, Germany. 3. Department of Medical Statistics, University Medicine Göttingen, Göttingen, Germany. 4. Department of Radiotherapy and Radiooncology, Ärztehaus am Diako, Bremen, Germany. 5. Department of Pathology, University Medicine Göttingen, Göttingen, Germany. 6. Department of Clinical Pharmacology, University Medicine Göttingen, Göttingen, Germany. 7. Department of Radiotherapy and Radiooncology, University Medicine Göttingen, Göttingen, Germany. hchrist@gwdg.de. 8. Universitätsmedizin Göttingen, Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Robert-Koch-Str. 40, 37075, Göttingen, Germany. hchrist@gwdg.de.
Abstract
PURPOSE: To test for a possible correlation between high-grade acute organ toxicity during preoperative radiochemotherapy and complete tumor regression after total mesorectal excision in multimodal treatment of locally advanced rectal cancer. PATIENTS AND METHODS: From 2001 to 2008, 120 patients were treated. Preoperative treatment consisted of normofractionated radiotherapy at a total dose of 50.4 Gy, and either two cycles of 5-fluorouracil (5-FU) or two cycles of 5-FU and oxaliplatin. Toxicity during treatment was monitored weekly, and any toxicity CTC (Common Toxicity Criteria) >or= grade 2 of enteritis, proctitis or cystitis was assessed as high-grade organ toxicity for later analysis. Complete histopathologic tumor regression (TRG4) was defined as the absence of any viable tumor cells. RESULTS: A significant coherency between high-grade acute organ toxicity and complete histopathologic tumor regression was found, which was independent of other factors like the preoperative chemotherapy schedule. The probability of patients with acute organ toxicity >or= grade 2 to achieve TRG4 after neoadjuvant treatment was more than three times higher than for patients without toxicity (odds ratio: 3.29, 95% confidence interval: [1.01, 10.96]). CONCLUSION: Acute organ toxicity during preoperative radiochemotherapy in rectal cancer could be an early predictor of treatment response in terms of complete tumor regression. Its possible impact on local control and survival is under further prospective evaluation by the authors' working group.
PURPOSE: To test for a possible correlation between high-grade acute organ toxicity during preoperative radiochemotherapy and complete tumor regression after total mesorectal excision in multimodal treatment of locally advanced rectal cancer. PATIENTS AND METHODS: From 2001 to 2008, 120 patients were treated. Preoperative treatment consisted of normofractionated radiotherapy at a total dose of 50.4 Gy, and either two cycles of 5-fluorouracil (5-FU) or two cycles of 5-FU and oxaliplatin. Toxicity during treatment was monitored weekly, and any toxicity CTC (Common Toxicity Criteria) >or= grade 2 of enteritis, proctitis or cystitis was assessed as high-grade organ toxicity for later analysis. Complete histopathologic tumor regression (TRG4) was defined as the absence of any viable tumor cells. RESULTS: A significant coherency between high-grade acute organ toxicity and complete histopathologic tumor regression was found, which was independent of other factors like the preoperative chemotherapy schedule. The probability of patients with acute organ toxicity >or= grade 2 to achieve TRG4 after neoadjuvant treatment was more than three times higher than for patients without toxicity (odds ratio: 3.29, 95% confidence interval: [1.01, 10.96]). CONCLUSION: Acute organ toxicity during preoperative radiochemotherapy in rectal cancer could be an early predictor of treatment response in terms of complete tumor regression. Its possible impact on local control and survival is under further prospective evaluation by the authors' working group.
Authors: A Dietz; V Rudat; C Conradt; B Vanselow; P Wollensack; S Staar; H Eckel; P Volling; M Schröder; M Wannenmacher; R P Müller; H Weidauer Journal: HNO Date: 2000-09 Impact factor: 1.284
Authors: Tiffany Daly; Michael G Poulsen; James W Denham; Lester J Peters; David S Lamb; Hedley Krawitz; Chris Hamilton; Jacqui Keller; Lee Tripcony; Quenten Walker Journal: Radiother Oncol Date: 2003-08 Impact factor: 6.280
Authors: Hans Christiansen; Robert M Hermann; Andrea Hille; Elisabeth Weiss; Mirko Nitsche; Alexios Martin; Clemens F Hess; Olivier Pradier Journal: Head Neck Date: 2004-10 Impact factor: 3.147
Authors: Roy F A Vliegen; Regina G Beets-Tan; Bart Vanhauten; Ann Driessen; Michel Oellers; Alfons G Kessels; Ann Arens; Geerard L Beets; Jeroen Buijsen; Angela van Baardwijk; Dirk de Ruysscher; Guido Lammering Journal: Strahlenther Onkol Date: 2008-09-19 Impact factor: 3.621
Authors: Hendrik Andreas Wolff; Jan Bosch; Klaus Jung; Tobias Overbeck; Steffen Hennies; Christoph Matthias; Clemens F Hess; Ralph M Roedel; Hans Christiansen Journal: Strahlenther Onkol Date: 2010-04-26 Impact factor: 3.621
Authors: Deborah Citrin; Kevin Camphausen; Bradford J Wood; Martha Quezado; John Denobile; James F Pingpank; Richard E Royal; H Richard Alexander; Geoffrey Seidel; Seth M Steinberg; Yvonne Shuttack; Steven K Libutti Journal: Oncology Date: 2011-03-25 Impact factor: 2.935
Authors: Hendrik Andreas Wolff; Steffen Hennies; Markus Karl Alfred Herrmann; Margret Rave-Fränk; David Eickelmann; Patricia Virsik; Klaus Jung; Markus Schirmer; Michael Ghadimi; Clemens Friedrich Hess; Robert Michael Hermann; Hans Christiansen Journal: Strahlenther Onkol Date: 2010-12-23 Impact factor: 3.621
Authors: J Joshua Smith; Isaac Wasserman; Sarah A Milgrom; Oliver S Chow; Chin-Tung Chen; Sujata Patil; Karyn A Goodman; Julio Garcia-Aguilar Journal: Int J Radiat Oncol Biol Phys Date: 2016-12-18 Impact factor: 7.038
Authors: Hans Theodor Eich; Anna Stepien; Christian Zimmermann; Martin Hellmich; Ralf Metzger; Arnulf Hölscher; Rolf-Peter Müller Journal: Strahlenther Onkol Date: 2011-03-07 Impact factor: 3.621